We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SemBioSys Obtains Rights to Platform-Enhancing Technologies from Syngenta
News

SemBioSys Obtains Rights to Platform-Enhancing Technologies from Syngenta

SemBioSys Obtains Rights to Platform-Enhancing Technologies from Syngenta
News

SemBioSys Obtains Rights to Platform-Enhancing Technologies from Syngenta

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SemBioSys Obtains Rights to Platform-Enhancing Technologies from Syngenta"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SemBioSys Genetics Inc. has announced an agreement to acquire technology assets and in-license intellectual property related to the manufacture of biopharmaceuticals in safflower from Syngenta Crop Protection AG

The assets and intellectual property will allow SemBioSys to further increase its efficiency in the development of transgenic safflower by shortening the time it takes to develop safflower plants producing the desired pharmaceutical protein.

Under the agreement, SemBioSys has issued warrants that allow Syngenta to purchase an aggregate of 550,000 common shares of SemBioSys at an exercise price of $13.21 per share, based on two times the trading price per share on the 20 day average trading price prior to issuing the warrant.

The term of the warrants is five years. The warrants will not be listed on the Toronto Stock Exchange.

"This technology will improve our productivity, expand our ability to make decisions earlier in the development process and allow us to accelerate new products into the clinic," said Andrew Baum, President and CEO of SemBioSys Genetics Inc.

"Our relationship with Syngenta started in 2003 and they became a shareholder in connection with our IPO in 2004."

"We see Syngenta's willingness to transfer this technology improvement, in return for our share purchase warrants, as a demonstration of their confidence in our ability to execute on our business plan using our plant-based pharmaceutical platform."

The agreement provides SemBioSys with a license to Syngenta's proprietary safflower transformation technology including all of Syngenta's improvements to safflower transformation and propagation as they apply to plant-made pharmaceuticals and other SemBioSys products.

SemBioSys also acquires information related to the safflower genome sequence and structure.

In November 2003, SemBioSys entered into a Technology License-Option Agreement with Syngenta Participations AG.

The current transaction provides SemBioSys with access to various technologies and assets developed by Syngenta under the Technology License-Option Agreement.

Advertisement